Abstract
Lung cancer is one of the most common malignant tumors and is the leading cause of cancer mortality worldwide. However, drug resistance induced by chemotherapeutants to lung cancer cells is the primary issue during the chemotherapy of lung cancer. Many mechanisms such as the changes of drug metabolism related genes and signal pathways are involved in chemoresistance. MicroRNAs (miRNAs) are a class of endogenetic, non-coding, short-chain and small RNAs that regulate cell growth, apoptosis and signal transduction. There are growing numbers of evidence suggesting that miRNA polymorphisms associate with drug metabolism and resistance. In addition, differentially expressed miRNAs play critical roles in the prediction of the sensitivity to chemotherapeutic agents in lung cancer. The recent progress demonstrates that regulation of specific miRNA expression will break novel paths for overcoming lung cancer resistance and the personalized therapy. Together, in this review we have discussed the current understanding of the role of miRNA on drug resistance, and the potential implications of miRNA in lung cancer targeted therapy.
Keywords: Drug resistance, metabolism, microRNA, polymorphism, targeted therapy.
Current Cancer Drug Targets
Title:Novel Insights Into the Role of MicroRNA in Lung Cancer Resistance to Treatment and Targeted Therapy
Volume: 14 Issue: 3
Author(s): Zhaohui Gong, Jie Yang, Jingqiu Li, Lihua Yang, Yanping Le, Shaomin Wang and Hui-Kuan Lin
Affiliation:
Keywords: Drug resistance, metabolism, microRNA, polymorphism, targeted therapy.
Abstract: Lung cancer is one of the most common malignant tumors and is the leading cause of cancer mortality worldwide. However, drug resistance induced by chemotherapeutants to lung cancer cells is the primary issue during the chemotherapy of lung cancer. Many mechanisms such as the changes of drug metabolism related genes and signal pathways are involved in chemoresistance. MicroRNAs (miRNAs) are a class of endogenetic, non-coding, short-chain and small RNAs that regulate cell growth, apoptosis and signal transduction. There are growing numbers of evidence suggesting that miRNA polymorphisms associate with drug metabolism and resistance. In addition, differentially expressed miRNAs play critical roles in the prediction of the sensitivity to chemotherapeutic agents in lung cancer. The recent progress demonstrates that regulation of specific miRNA expression will break novel paths for overcoming lung cancer resistance and the personalized therapy. Together, in this review we have discussed the current understanding of the role of miRNA on drug resistance, and the potential implications of miRNA in lung cancer targeted therapy.
Export Options
About this article
Cite this article as:
Gong Zhaohui, Yang Jie, Li Jingqiu, Yang Lihua, Le Yanping, Wang Shaomin and Lin Hui-Kuan, Novel Insights Into the Role of MicroRNA in Lung Cancer Resistance to Treatment and Targeted Therapy, Current Cancer Drug Targets 2014; 14 (3) . https://dx.doi.org/10.2174/1568009614666140305104845
DOI https://dx.doi.org/10.2174/1568009614666140305104845 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biological Relevance of DNA Polymerase Beta and Translesion Synthesis Polymerases to Cancer and its Treatment
Current Molecular Pharmacology CRIM1, the Antagonist of BMPs, is a Potential Risk Factor of Cancer
Current Cancer Drug Targets Is DNA Minor Groove Binding Crucial for Biological Activity of Triazoloacridinones with Cytotoxic and Antitumour Properties?
Letters in Drug Design & Discovery Targeting Leptin as a Therapeutic Strategy against Ovarian Cancer Peritoneal Metastasis
Anti-Cancer Agents in Medicinal Chemistry Anticancer Activity and Mechanism Investigation of Beauvericin Isolated from Secondary Metabolites of the Mangrove Endophytic Fungi
Anti-Cancer Agents in Medicinal Chemistry Editorial (Hot Topic:Recent Advance in the Studies of Beta-glucans for Cancer Therapy)
Anti-Cancer Agents in Medicinal Chemistry c-Myc and Downstream Targets in the Pathogenesis and Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Recent Progress in Chemosensors Using Aldehyde-bearing Fluorophores for the Detection of Specific Analytes and their Bioimaging
Current Medicinal Chemistry Emerging Roles of Cysteine Cathepsins in Disease and their Potential as Drug Targets
Current Pharmaceutical Design Recent Patents on Proteasome Inhibitors of Natural Origin
Recent Patents on Anti-Cancer Drug Discovery Biodistribution, Safety and Organ Toxicity of Docetaxel-Loaded in HER-2 Aptamer Conjugated Ecoflex® Nanoparticles in a Mouse Xenograft Model of Ovarian Cancer
Recent Patents on Nanotechnology Understanding Apoptosis in Terms of QSAR
Anti-Cancer Agents in Medicinal Chemistry Glycogen Metabolism and Brain Pathologies
Central Nervous System Agents in Medicinal Chemistry Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Anti-Cancer Agents in Medicinal Chemistry Perspective of MiRNAs in Clinical Glioblastoma Research
Current Signal Transduction Therapy Antineoplastic Effects of PPARγ Agonists, with a Special Focus on Thyroid Cancer
Current Medicinal Chemistry Major Challenges for Gene Therapy of Thalassemia and Sickle Cell Disease
Current Gene Therapy Determination of Mutation Pattern in Human Androgen Receptor by Means of Amino-Acid Pair Predictability
Protein & Peptide Letters Therapeutic and Diagnostic Applications of Nanoparticles
Current Drug Targets The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets